ChinaDaily Briefs

Daily Brief China: Shengjing Bank Co Ltd H, Horizon Robotics, Alibaba, Montage Technology , PC Partner, NetEase , Nongfu Spring , Mixue Group, CSPC Pharmaceutical Group and more

In today’s briefing:

  • Shengjing Bank (2066 HK): A Light Conditional VGO and Delisting Proposal
  • [Quiddity Index] Sep25 HS Internet & IT Index Review; Capping Methodology Changes, Flows 20% Higher
  • Alibaba (9988 HK): Top Trades Ahead of Earnings
  • Montage Technology A/H Listing – Fast Growth but Doesn’t Need the Cash, Delisted Once
  • PC Partner: 1H25 Results Show Progress, To Delist from HK by End of FY25
  • Tencent/Netease: Netease and Bilibili Got One Each in August
  • Shengjing Bank (2066 HK): Dire Status, Dire Offer Price
  • Nongfu (9633 HK): 1H25, Recovering from Defamation, Record High Margin
  • MIXUE IPO Lockup – US$480m Cornerstone Lockup Release
  • CSPC Pharma (1093 HK): Finished Drugs Drag 1H25; 2H25 Expected To End with More Licensing Deals


Shengjing Bank (2066 HK): A Light Conditional VGO and Delisting Proposal

By Arun George

  • Shengjing Bank Co Ltd H (2066 HK) disclosed a voluntary conditional offer and delisting proposal by Shenyang SASAC at HK$1.32 per H Share, a 15.8% premium to the undisturbed price.
  • The key conditions are H Shareholder approval of the delisting and a minimum acceptance condition (50% of outstanding and 90% of H Shares). The offer has NOT been declared final.
  • The offer is unattractive compared to precedent transactions, peer multiples and historical trading ranges. The satisfaction of the minimum acceptance condition is the key risk.  

[Quiddity Index] Sep25 HS Internet & IT Index Review; Capping Methodology Changes, Flows 20% Higher

By Travis Lundy

  • On Friday 22 August, the Hang Seng Index team announced the changes to the Hang Seng Internet and IT Index for the September 2025 rebalance.
  • There are 3 ADDs and 3 DELs. We predicted 2/3 ADDs and 3/3 DELs correctly. But Funding and FAF Re-weight/Capping flows are bigger than the ADD/DEL flows.
  • Then on Monday 25 August, the index provider announced a capping methodology change. Not much changes, but flows increase from US$850mm to US$1bn+. Tables and spreadsheets amended.

Alibaba (9988 HK): Top Trades Ahead of Earnings

By Gaudenz Schneider

  • Alibaba (9988 HK) will announce quarterly results on Friday, August 29, 7:30 p.m. Hong Kong Time.  In the lead-up, options strategies on the Hong Kong Exchange showcase a variety of approaches.
  • Highlights: Recent option trades show a bias towards bullish sentiment. Two strategies using weekly options expiring soon after the earnings announcement are explored.
  • Why Read: This review offers real-market insight into how sophisticated participants are positioning ahead of Tencent’s earnings.

Montage Technology A/H Listing – Fast Growth but Doesn’t Need the Cash, Delisted Once

By Sumeet Singh

  • Montage Technology (688008 CH) (MT), a provider of memory interface chips and interconnect chips, aims to raise around US$1bn in its H-share listing.
  • MT’s product portfolio, mainly comprises memory interface chips and interconnect chips, addresses interconnect bottlenecks while enhancing data rate/bandwidth, reliability, and power efficiency, as per the company.
  • In this note, we look at its past performance and other deal dynamics that might impact the listing.

PC Partner: 1H25 Results Show Progress, To Delist from HK by End of FY25

By Nicolas Van Broekhoven

  • PC Partner reported 1H25 results, which showed strong revenue growth and flat net margins.
  • The company is confident it can delist from HK before the end of the year, as it only needs 50% of shareholders to approve the transaction. SGX only listing remaining.
  • The company is now part of the Nvidia Partnership Network, which could accelerate growth in FY26.

Tencent/Netease: Netease and Bilibili Got One Each in August

By Ke Yan, CFA, FRM

  • China announced game approval for the August batch. The number of games approved remained at a higher level than 2023.
  • The number of game approval in August marked the record high level since the resumption post tightening.
  • Of the companies that we are monitoring, Netease and Bilibili got approval for one game each.

Shengjing Bank (2066 HK): Dire Status, Dire Offer Price

By David Blennerhassett

  • HK$1.32/Share, a 15.79% premium to undisturbed, and a massive 86.49% discount to NAV. For a rural commercial bank privatisation, there is nothing pretty in those numbers.
  • Even the Offers for Bank Of Jinzhou (416 HK) and Jilin Jiutai Rural Comm Bank (6122 HK) were pitched (slightly) higher, from a P/NAV standpoint. And both were perennially suspended.
  • This is privatisation via a voluntary offer, NOT a privatisation via a Merger by Absorption. As such there is scheme-like vote AND a 90% tendering condition.

Nongfu (9633 HK): 1H25, Recovering from Defamation, Record High Margin

By Ming Lu

  • Nongfu Spring’s revenue increased by 16% YoY in 1H25, compared to a decrease of 7% YoY in 2H24.
  • The operating margin reached its historical high, 37%, since the company’s IPO.
  • Wahaha, the competitor that defamed Nongfu, is in a scandal itself.

MIXUE IPO Lockup – US$480m Cornerstone Lockup Release

By Sumeet Singh

  • Mixue Group (2097 HK) raised around US$450m in its Hong Kong IPO in March 2025. The lockup on its cornerstone investors is set to expire soon.
  • MIXUE Group (MIXUE) is a freshly-made drinks company providing affordable products to consumers, including freshly-made fruit drinks, tea, ice cream and coffee, typically priced at around one USD per item.
  • In this note, we will talk about the lockup dynamics and possible placement.

CSPC Pharma (1093 HK): Finished Drugs Drag 1H25; 2H25 Expected To End with More Licensing Deals

By Tina Banerjee

  • CSPC Pharmaceutical Group (1093 HK) 1H25 revenue dropped 18.5% YoY as finished drugs witnessed decrease on VBP and NRDL inclusion. Bulk products and license fees compensated to an extent.
  • More license and collaboration in relation to the development, manufacturing and commercialization of certain products of the company awaited in 2H25 and augurs well in terms of future revenue visibility.
  • CSPC Pharmaceutical aims to expand into the high-end market to achieve competitive differentiation and thereby command higher prices.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars